Does boron neutron capture therapy regress cancer?

Simple item page
dc.contributor.authorMallesch, JLen_AU
dc.contributor.authorAllen, BJen_AU
dc.contributor.authorMoore, DEen_AU
dc.date.accessioned2025-11-24T02:06:13Zen_AU
dc.date.available2025-11-24T02:06:13Zen_AU
dc.date.issued1991-10-02en_AU
dc.date.statistics2025-11-13en_AU
dc.descriptionPhysical copy held by ANSTO Library at DDC: 571.45/15en_AU
dc.description.abstractIn recent years a range of animal and human studies have been carried out on the uptake of boron compounds by neoplasms and their regression by Boron Neutron Capture Therapy (BNCT). Results will be presented for experiments with mice, rats rabbits, pigs, dogs and human patients from laboratories in Europe, USA, Japan and Australia. Most of the tumour xenograft models have centred upon melanoma and glioma cancers. In addition, the majority of the biodictribution studies have involved the use of Borocaptate Sodium (BSH) and Boronophenylalanine (BPA) which have shown the most promise for BNCT. Other more recently developed compounds,which have also been trialed in rodent species, are BSSB and BOPP. Tumour to blood boron ratios achieved after administration of BSH are in the order of 2-3. This ratio is improved to approximately 8-12 if BPA is administered. Tumour to normal tissue boron ratios for both BPA and BSH arc in the range of 3-5. Where NCT has been employed, either thermal and epithermal neutron beams have been utilised. The therapeutic boron concentration required in the tumour is approximately 15-30 ppm. In all experiments using the thermal neutron bean, in conjunction with the boron compounds, have resulted in complete regression in approximately 60% of cases. In some models this success is as high as 80%. This paper will review specific models, boron biodistributions attained as well as preclinical and clinical results achieved by treatment with BNCT.en_AU
dc.identifier.booktitle13th AINSE Radiation Biology Conference, 2-4 October 1991, Lucas Heights - AINSE Theatre : conference handbook (programme, abstracts and general information)en_AU
dc.identifier.citationMallesch, J. L., Allen, B. J., & Moore, D. E. (1991). Does boron neutron capture therapy regress cancer? Presentation to the 13th AINSE Radiation Biology Conference, 2-4 October 1991, Lucas Heights - AINSE Theatre : conference handbook (programme, abstracts and general information), (pp. 49). Lucas Heights, New South Wales : AINSE.en_AU
dc.identifier.conferenceenddate1991-10-04en_AU
dc.identifier.conferencename13th AINSE Radiation Biology Conferenceen_AU
dc.identifier.conferenceplaceLucas Heights, New South Walesen_AU
dc.identifier.conferencestartdate1991-10-02en_AU
dc.identifier.pagination49en_AU
dc.identifier.placeofpublicationLucas Heights, New South Walesen_AU
dc.identifier.urihttps://apo.ansto.gov.au/handle/10238/16734en_AU
dc.language.isoenen_AU
dc.publisherAINSEen_AU
dc.subjectBiological recoveryen_AU
dc.subjectBoron compoundsen_AU
dc.subjectDataen_AU
dc.subjectExperimental dataen_AU
dc.subjectExperimental neoplasmsen_AU
dc.subjectMelanomasen_AU
dc.subjectNeoplasmsen_AU
dc.subjectNeutron capture therapyen_AU
dc.subjectPerformanceen_AU
dc.subjectThermal neutronsen_AU
dc.titleDoes boron neutron capture therapy regress cancer?en_AU
dc.typeConference Abstracten_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Conference Publications